IRIDEX Corporation (IRIX) Earnings Call Transcript & Summary
March 26, 2026
What were the key takeaways from IRIDEX Corporation's March 26, 2026 earnings call?
IRIDEX Corporation reported its Q4 2025 and full-year results, highlighting a 16% YoY revenue growth for the quarter and 8% for the year, reaching $52.7 million. The company achieved positive adjusted EBITDA and cash flow from operations for the first time, marking a significant financial transformation. Management provided 2026 revenue guidance of $51 million to $53 million, excluding Middle East sales, indicating a 1% to 5% growth. The focus on cost reduction and strategic initiatives, such as transitioning to third-party manufacturing, is expected to improve margins and profitability.
What topics did IRIDEX Corporation cover?
- Revenue Growth: Q4 2025 revenue increased by 16% YoY to $14.7 million, driven by higher retina and glaucoma probe sales. Full-year revenue grew 8% to $52.7 million. Management noted, 'Fourth quarter growth was even stronger. The 16% increase marked the strongest quarterly growth rate of the year.'
- Cost Reduction Initiatives: IRIDEX reduced operating expenses by 22% YoY and plans further savings by relocating headquarters and transitioning to third-party manufacturing. Management expects these moves to 'generate approximately $165,000 in quarterly savings beginning in Q1, 2026.'
- Glaucoma Business Performance: The Cyclo G6 glaucoma product family saw a 15% YoY revenue increase in Q4 2025, with 15,900 probes sold. Management highlighted, 'We are well positioned to drive meaningful G6 growth throughout 2026.'
- Retina Portfolio Expansion: Retina product revenue increased 22% YoY in Q4 2025, driven by PASCAL system sales. Management emphasized, 'PASCAL is firmly established as our flagship system.'
- Middle East Market Impact: Sales in the Middle East are materially impacted by the conflict in Iran, leading to exclusion from 2026 guidance. Management noted, 'This guidance contemplates no sales in the Middle East.'
What were IRIDEX Corporation's March 26, 2026 results?
- Revenue: $14.7M (vs $12.7M in Q4 2024, +16% YoY)
- Full-Year Revenue: $52.7M (+8% YoY)
- Gross Margin: 37% (vs 44% in Q4 2024)
- Operating Expenses: $5.5M (-10% YoY)
- Net Loss: $0.2M (vs $0.8M loss in Q4 2024)
- Adjusted EBITDA: $817,000 (vs $611,000 in Q4 2024)
IRIDEX's financial transformation with cost reductions and strategic initiatives positions it well for sustainable profitability. However, geopolitical risks and gross margin pressures remain concerns. Investors should monitor the execution of cost-saving measures and the impact of geopolitical developments on revenue growth.
Earnings Call Speaker Segments
Thanks for holding. I'm Jordan, and I'll be handling the conference operator duties for you today. Right now, I'd like to extend a welcome to each of you joining the IRIDEX Corporation Earnings Conference Call for Q4 2025. Every line has been muted; a question-and-answer session is going to take place. Should you wish to pose a question while that session is happening, just hit star and then the number one on your phone's keypad. Should you wish to pull back your question, hit star one once more. I appreciate it. At this point, I'd like to hand things over to Trip Taylor from Investor Relations. The floor is yours. Thanks, and I appreciate all of you for being part of today's call.
On today's call with us from the company are Patrick Mercer, who serves as Chief Executive Officer of IRIDEX Corporation, and Romeo Dizon, its Chief Financial Officer. IRIDEX Corporation put out its financial results earlier today covering the quarter that closed on 01/03/2026. You can find a copy of that press release posted on the company's website. Before we get started, I want to remind everyone that during this call, management will be making statements that constitute forward-looking statements under federal securities laws, and these are being made in reliance on the safe harbor protections set out in the Private Securities Litigation Reform Act of 1995. Any statements on this call that aren't statements of historical fact — including, without limitation, statements about our strategic goals and priorities, matters relating to product development, sales trends, and the markets where we operate — all such forward-looking statements rest on our present estimates and a range of assumptions; they carry material risks and uncertainties that might cause actual results or events to differ materially from what those forward-looking statements anticipate or imply. As a result, you shouldn't rely on these statements. For a discussion of the risks and uncertainties tied to our business, please refer to our most recent Form 10-Ks and Form 10-Q filed with the SEC. Except where the law requires it, IRIDEX Corporation disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events, or otherwise; this conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 26, 2026. I'll now hand the call over to Patrick.
Thank you, Trip. Hello, everyone, and I appreciate you being with us this afternoon. It's a pleasure to report our results for the fourth quarter and the full year, reflecting a successful 12 months and a favorable transformation here at IRIDEX Corporation. During 2025, we met the objectives we set to simplify how we operate, bring expenses down, and place IRIDEX Corporation on a trajectory toward lasting profitability; across full-year 2025, our revenue rose 8% while operating expenses fell 22% against the previous year. That operating leverage allowed us to post positive adjusted EBITDA for the first time in the company's recent history. On top of that, we finished the year with positive cash flow from operations during the fourth quarter. I think it's evident that we've completed the necessary work to establish a fresh financial profile that can produce positive cash flow from operations in 2026 and beyond. Revenue for the full year came to $52.7 million, which is 8% growth year over year against 2024. Importantly, we recorded growth in each major product category — Cyclo G6, medical retina, surgical retina — and in both our U.S. and international businesses. Our fourth-quarter growth was even more impressive. That 16% gain represented the highest quarterly growth rate we saw all year. Let me spend a moment pointing out several key contributors behind our strong Q4 performance. When it comes to costs, we keep right-sizing the business so it aligns better with revenues. We've made continued meaningful progress relocating certain general and administrative functions out of California; on its own, we anticipate this initiative will produce roughly $165,000 in quarterly savings starting in Q1 2026. Later in 2026, we also intend to move our headquarters, which will trim our fixed cost base further by about $600,000 on an annualized basis. In addition, as we keep working to lower our cost structure, we're actively talking with contract manufacturers as part of a multiyear initiative to shift production away from our Mountain View facilities toward lower-cost third-party manufacturing. We anticipate starting meaningful transfers in 2026, which will progressively reduce our cost of goods as the year goes on. We expect full implementation to wrap up in 2027, delivering yet another meaningful reduction to our cost of goods. Over the years ahead, this initiative should serve as a significant driver of gross margin improvement. Now let's turn to a closer look at our commercial results. For the fourth quarter, starting with our glaucoma business. In the United States, our strategy continues to focus on capitalizing on our substantial installed base of Cyclo G6 systems and pushing procedural utilization higher. Medicare LCDs brought in last year keep creating catalysts for G6 adoption earlier in the continuum of care for patients with mild- to moderate-stage disease. Our team is concentrated on teaching our physician users about this opportunity, which includes emphasizing our strong clinical data backing the IOP-lowering efficacy of the procedure along with the updated sweep speed procedural technique. With MedScout—our fairly recent platform for sales enablement—we're pinpointing accounts sitting in the middle band of utilization so we can connect with clinicians and reinforce what makes our repeatable, incisionless procedure so beneficial. As a further step in that same push, we're now going after MIGS surgeons who handle high volumes and, judging by their case counts, could bring the procedure on board at utilization levels that matter. Favorable pricing, tied to the greater value of what we offer, also gave Q4 glaucoma revenue a lift. Doctors moving their practices generated quite a few system sales during the quarter, since those new locations needed their own dedicated G6 units. Between an installed base that keeps expanding, stronger ASPs, and commercial targeting that gets better all the time thanks to MedScout, we're in a good spot to deliver substantial G6 growth across all of 2026. All told, during the fourth quarter, 15,900 probes went out the door, compared with 13,300 a year earlier, along with 44 G6 systems, versus 47 in Q4 2024. Across the whole of 2025, we moved 57,800 Cyclo G6 probes, up against 55,400 the year before, and 133 G6 systems, compared with 125 in 2024. International glaucoma also came in strong across a number of geographies; in Europe, the Middle East, and Africa, probe sales for glaucoma rose for a third quarter in a row, helped along by several GPI orders being fulfilled—a milestone that means a lot for that region. Worth noting: the conflict in Iran is materially hurting Middle East sales right now; in GmbH, G6 probe sales are holding steady among existing customers, and we think our GmbH utilization is positioned well to take on added volume as we navigate distributor transitions there; in Asia, the region kept facing volatility and operational difficulties. Even with demand persisting, changing macroeconomic conditions keep weighing on our commercial activity. Tariff uncertainty with China keeps evolving and continues to make sales and forecasting difficult; in Japan, present headwinds keep dragging on near-term results. Our partnership with Topcon is still in place, and we're watching the macro environment carefully, expecting things to get better down the road. In Latin America and Canada, the region posted stable G6 probe utilization, which speaks to solid uptake of our technology in Canada and across key markets; moving now to our retina portfolio, our leading priorities remain seizing the ongoing upgrade cycle, advancing PASCAL adoption both at home and abroad, and obtaining further regulatory clearances for our next-generation retina platforms so we can leverage our global distribution network. Within the United States, PASCAL stands firmly as our flagship system, and we keep seeing a steady pattern of existing PASCAL customers moving up to our newer platforms. On top of that, ophthalmologists just finishing training are picking IRIDEX Corporation's PASCAL systems, partly because of our work to make PASCAL the go-to system in university and training programs. Medical and surgical retina revenue turned in a good performance. Surgical retina stood out in particular, beating the plan for the quarter. EndoProbe sales stayed level through Q4, showing steady results. Now to international retina. In Europe, Middle East and Africa, the region kept delivering in line with what we expected. PASCAL's results across the Middle East and Africa came in a bit weaker during Q4, after we had fulfilled a number of sizable orders in Q3. We're likewise gaining ground on growing our E&C operation in the U.K., with meaningful gains in ENT probes and IQ 532 XP systems. Italy is holding steady, and we keep working on distributor quality and service there. Retina product sales in the Middle East are additionally taking a significant hit from the conflict in Iran. Over at GmbH, capital equipment revenue ran into a downturn, partly because purchase orders were delayed. Even so, we closed our first IQ 532 XP sales in Germany, and we see this as an encouraging new approach for growing the business. Our GmbH team has booked PASCAL Synthesis orders and keeps developing a pipeline for placements involving newer models while MDR certification is pending. Turning to Asia, our retina business felt the same macro forces weighing on glaucoma throughout the region, among them the China tariff situation and currency pressure in Japan. Even with those headwinds, underlying demand for retina products across Asia stays solid, and we see the region as offering meaningful upside once operational uncertainty clears up. In Latin America and Canada, things keep stabilizing, helped by steady PASCAL sales that come from renewed distribution engagement in Chile and Colombia. As a sign of our broad commercial push, it's worth highlighting that clinician interest in our glaucoma and retinal laser platforms was highly evident at the American Academy of Ophthalmology annual meeting. Our booth location drew considerable foot traffic. It's encouraging to see rising attention to our industry-leading technology, and we left the meeting with a big number of high-quality leads. Even more important, when it comes to execution, our sales team did a remarkable job turning those leads into orders, with close to $1,000,000 in business coming directly out of that meeting. We anticipate continuing to carry out our strategic initiatives and to build on our commercial momentum with our glaucoma and retina platforms in order to drive revenue growth in 2026. For the year, revenue should fall in the range of $51,000,000 to $53,000,000. That guidance assumes no sales in the Middle East. If adjusted to remove Middle East revenue in 2025, our guidance works out to 2026 growth of 1% to 5%. I'll now hand the call over to Romeo Dizon to go over our financial results.
Thanks, Patrick. Good afternoon, everyone, and I appreciate you joining us today. Before I take you through the quarter's financial results, I should note that fiscal year 2025 had 53 weeks, and the fourth quarter spanned 14 weeks, while the comparable period a year ago had 13 weeks. As we said in our press release and in Patrick's remarks, total revenues for 2025 reached $14,700,000, a 16% increase year over year, up from $12,700,000 in 2024. The growth was driven mainly by stronger retina sales, including PASCAL sales, as well as sales of glaucoma probes. Retina product revenue rose 22% in 2025, hitting $8,900,000 compared with 2024, chiefly on higher PASCAL system sales and medical and surgical retina system sales. Revenue from products in the Cyclo G6 glaucoma family was $3,800,000, up 15% year over year, mainly on the strength of higher probe sales. Other revenues declined by $100,000 to $2,000,000 in 2025, from $2,100,000 in 2024. Gross profit for 2025 was $5,500,000, a gross margin of 37%, which is $100,000 below the $5,600,000, or 44% gross margin, recorded in 2024. That decline was driven primarily by higher overall manufacturing costs, including greater product costs tied to tariff developments over the course of the year, along with reduced capitalization of manufacturing overhead as our inventory levels came down. Operating expenses for 2025 totaled $5,500,000, down $600,000, or 10%, from $6,100,000 in 2024, reflecting the cost-cutting steps we took late in 2024. Net loss for 2025 was $200,000, or $0.01 per share, compared with a net loss of $800,000, or $0.05 per share, in the equivalent period the year before. The 2025 net loss included a $100,000 provision for income tax and $100,000 of interest expense. Non-GAAP adjusted EBITDA for 2025 was $817,000, which is $200,000 better than the non-GAAP adjusted EBITDA of $611,000 for 2024. That improvement is mainly attributable to the expense reduction measures put in place late in 2024. Cash and cash equivalents stood at $6,000,000,000 when the fourth quarter of 2025 ended, which is $400,000 more than the $5,600,000 on hand at the close of 2025. During 2025, cash use was $2,100,000, an improvement of 71% over 2024. We're quite happy with how much we've cut our cash usage, and we expect cash use to keep improving or at least hold at these levels. Although gross margin is a major factor in strengthening our financial profile, we saw a decline in 2025, largely because of higher overall manufacturing costs, including greater product costs related to tariff developments throughout the year, and reduced capitalization of manufacturing overhead as inventory levels fell. For the full year 2025, our gross margins also came down because of inventory write-downs, along with the same factors behind the fourth-quarter decline. We anticipate gross margins will get better as we move through the manufacturing transition to third-party contract manufacturers across 2026 and 2027. Looking ahead, we expect cash use in the range of $19 million to $19.5 million. During Q4, our operating expenses continued trending favorably, reflecting the durable impact of the cost-reduction actions we began implementing in Q4 2024. For the full year 2025, operating expenses declined 22% compared with the previous year. Relocating certain G&A positions outside of California, which kicks off in 2026, is expected to generate savings of about $165,000 per quarter starting in Q1 2026; we're very pleased to report that we achieved positive adjusted EBITDA for all of 2025, exactly as we had pledged at the outset of the year. Achieving positive cash flow was another significant milestone in 2025. Our cash and cash equivalents as of the end of Q4 demonstrate how substantially we've reduced our cash burn, and we expect to maintain that same trajectory throughout 2026. Bear in mind that, generally speaking, our largest cash consumption occurs during the first quarter of the fiscal year, since that's when we settle accrued compensation as well as other accrued expenses and liabilities. Throughout the remaining quarters of the year, we expect to generate cash, and we anticipate quarterly cash generation will grow sequentially as inventory is sold through and receivables are collected on higher revenues. Combined, that yields positive cash flow for fiscal year 2026. As Patrick mentioned, we're introducing our 2026 guidance; we expect revenues to fall between $51,000,000 and $53,000,000. Due to market disruption related to the ongoing conflict in the Middle East, that guidance excludes revenue from the region. On a pro forma basis, adjusted to strip out Middle East revenue in 2025, the guidance translates to 2026 growth of 1% to 5% over 2025. We'd also like to reiterate the seasonality our business experiences. Q1 typically represents 22% of annual revenue and is the smallest quarterly revenue figure of the year. In terms of total dollars, Q2 and Q4 are seasonally stronger than Q1, with Q4 being the strongest quarter of the year, while Q3 generally reflects a sequential decline from Q2. We've provided expectations for adjusted operating expenses, which exclude depreciation and amortization and stock compensation, to fall within the range of $19,000,000 to $19,500,000 — or, to put it another way, $19 million to $19.5 million. With that, I'll turn the call back over to Patrick.
Romeo, thanks. Thinking back over the last twelve months, the team here at IRIDEX Corporation has achieved a great deal that makes me proud. Back in Q4 2024, when this transformation got underway, our goals were to increase revenue, bring operating expenses down, strengthen our financial profile, and get the business ready for lasting profitability — and all four of those, we're glad to report, have been achieved. As we look ahead to 2026, we know exactly where our focus belongs. On the growth front, we're working to widen the G6 user base, going after high-volume MIGS surgeons through MedScout intelligence, and at the same time we'll keep pushing utilization higher across the installed base we already have. On the retina side, we're chasing regulatory clearances abroad so we can open up new geographies, and at home we're speeding up the replacement cycle for our PASCAL installed base; when it comes to costs, our shift toward contract manufacturing will carry on, we'll keep production at our headquarters to a minimum, and we'll move the facility relocation forward. We appreciate your ongoing backing of IRIDEX Corporation, and we can't wait to bring you up to date on how things are going next quarter. Thank you.
Just a quick note — anyone wanting to pose a question should hit star one on their phone's keypad. Scott Henry, who is with Alliance Global, is up first. Go ahead, your line is open.
Thanks, and good afternoon. I have just a few questions. To start, as we consider your 2026 guidance, what size is the Middle East when it comes to revenues? What share of the revenue base does it represent?
Hi, Scott; that region accounts for 5% of our overall revenue base and 10% of U.S.
Hey, Patrick, thanks. So that's bigger than what we'd usually see for that region. And when I look at Q4, I also saw that the other line item dropped quarter over quarter. Is that simply normal fluctuation, or are there some patterns at play, with it coming down from Q3 in that other segment?
Segment? Could you repeat that, Scott? What are you referring to when you mention the other segment?
Turning to the other revenue line. That comes to roughly $2,000,000; last quarter, as I recall, it stood at $2.2 million, and $2.2 million the quarter before that — I mean, these aren't large figures — but
What drives this is essentially the service product lines, and not truly — some months we simply receive a batch of service work to deliver. In other months, well, you know, it's fairly flat; it remains at roughly that same level, give or take $100,000.
All right, that's reasonable. And then, regarding G6, we don't have — I'll obtain the detailed breakdowns, but going only by what was said generally — it seems like pricing declined somewhat versus the prior two quarters when compared with units sold and probe usage. Would that be accurate, and does that represent a pattern or merely, you know, quarter-to-quarter fluctuation?
No. Actually, if you examine consolidated figures, the OUS must be what pushed that lower, since both OUS and the U.S. saw us raise ASPs for the probes. Additionally, volume has risen and kept rising through this quarter.
Correct, and over the past year as well as this one, we've raised average selling prices on the probes and on the system for global — meaning within the U.S.
All right. I suppose I'll examine that once the K gets filed too. One last thing. Regarding the retina segment, and to some extent the G6 segment, what's your thinking on organic growth rates, especially for retina? What sort of steady-state, or organic, growth rate ought we to assume for that segment?
Scott, I'd say, when we spoke four or five years back, our expectation was always that revenue would fall by roughly 1% to 2%. Then, following my departure, the company went and merged with or acquired Topcon, and we picked up the PASCAL systems. So in my own view, considering how large this distribution model is along with the product itself, PASCAL, which is truly turning into our flagship offering in the U.S., it has genuinely driven either a modest uptick in the product business over the past couple of years.
All right. So I guess what you're saying is — assuming that category expands by roughly 4%, do you still believe your share is rising within retina? Put another way?
Without a doubt. You know, thanks to our PASCAL, there's considerable momentum behind that product as we move ahead. Compared with what else is on the market, it's quicker. It gets serviced out in the field. And its performance is really strong. Plus, as additional MDR approvals come through around the world, we'll watch that accelerate. It's already gained traction in the U.S., and with more clearances arriving, it will certainly accelerate. That growth is something we anticipate seeing.
All right, appreciate you letting us ask.
You're welcome, Scott.
That brings us to the end of the question-and-answer portion. Now I'll hand things over to Patrick Mercer, who has some final thoughts for us.
Wonderful. Thanks to all of you for being here today. We'll keep sharing updates about how things are going, and we're grateful for the questions you raised. Thanks so much.
That concludes today's meeting. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete IRIDEX Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to IRIDEX Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.